Results 81 to 90 of about 1,936 (153)
Background A challenge in the empiric treatment of complicated urinary tract infection (cUTI) is identifying the initial appropriate antibiotic therapy (IAAT), which is associated with reduced length of stay and mortality compared with initial ...
Teresa L Kauf +7 more
doaj +1 more source
Introduction Hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP) are associated with significant healthcare resource utilization (HCRU).
Thomas Lodise +4 more
doaj +1 more source
Michael Pfaller,1,2 Dee Shortridge,1 Wei-Ting Chen,3 Helio Sader,1 Mariana Castanheira1 1JMI Laboratories, North Liberty, IA, USA; 2University of Iowa College of Medicine, Iowa City, IA, USA; 3Merck & Co., Inc, Kenilworth, NJ, USACorrespondence: Dee ...
Pfaller M +4 more
doaj
Objectives: To develop a scoring system to predict resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa strains isolated from respiratory specimens.
ÇAKIR, BANU +7 more
core +1 more source
Guidelines for the treatment of sepsis, febrile neutropenia, and hospital-acquired pneumonia caused by Pseudomonas aeruginosa include empirical regimens incorporating two antibiotics from different classes with activity against
Kellie J. Goodlet +2 more
core +1 more source
Two pairs of ceftolozane/tazobactam susceptible/resistant P. aeruginosa were isolated from 2 patients after exposure to β-lactams. The genetic basis of ceftolozane/tazobactam resistance was evaluated, and β-lactam-resistant mechanisms were assessed by ...
Erik Skoglund +11 more
doaj +1 more source
Ceftolozane/tazobactam: Novelantipseudomonal cephalosporin [PDF]
Abstract Another much-needed antibiotic enters the marketplace with FDA'sapproval of ceftolozane/tazobactam (Zerbaxa—Cubist) for the treatmentof adult patients with complicated intra-abdominal infections(cIAI) in combination with metronidazole and for complicated urinarytract infections (cUTI), including pyelonephritis.
openaire +1 more source
Objectives Ceftolozane/tazobactam is a relevant option for treating multiresistant Pseudomonas aeruginosa, a major public health problem. Over a 14-month period, we studied the frequency of ceftolozane/tazobactam resistance development and mechanisms ...
Léa Bientz +13 more
doaj +1 more source
ObjectivesTo investigate the in vitro susceptibility of recent clinical Enterobacterales and Pseudomonas aeruginosa isolates collected in the Arabian Gulf region to ceftolozane/tazobactam, imipenem/relebactam, and comparator antimicrobial agents ...
Mark G. Wise +5 more
doaj +1 more source
Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections [PDF]
Marion J Skalweit1,2 1Department of Medicine, 2Department of Biochemistry, Louis Stokes Cleveland Department of Veterans Affairs and Case Western Reserve University School of Medicine, Cleveland, OH, USA Abstract: Drug-resistant pathogens have gained a
Skalweit MJ
core

